Endocrine Abstracts

Introduction: First-line somatostatin analogue treatment may be an effective alternative option to surgery for some patients with GH-secreting pituitary macroadenoma. The PRIMARYS study aimed to investigate the impact of primary lanreotide Autogel 120 mg treatment on tumour volume and GH/IGF1 control in treatment-naïve acromegalic patients over a one-year time course.Methods: PRIMARYS was an international, multicentre, open-label, single arm, phase ...

Introduction: Generously supported by IPSEN)-->Surgery is recognized first-line therapy for acromegalic patients but tumour size and GH/IGF1 control has also been observed after primary somatostatin analogue treatment. This is the first study of therapy with high-dose lanreotide Autogel over one year in a large cohort of treatment-naïve acromegalic patients.Methods: In this international, multicentre, open...